ATE268604T1 - Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren - Google Patents

Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren

Info

Publication number
ATE268604T1
ATE268604T1 AT96906260T AT96906260T ATE268604T1 AT E268604 T1 ATE268604 T1 AT E268604T1 AT 96906260 T AT96906260 T AT 96906260T AT 96906260 T AT96906260 T AT 96906260T AT E268604 T1 ATE268604 T1 AT E268604T1
Authority
AT
Austria
Prior art keywords
beta
lymphotoxin
activating agent
lhc
carrier
Prior art date
Application number
AT96906260T
Other languages
English (en)
Inventor
Jeffrey L Browning
Werner Meier
Christopher D Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE268604T1 publication Critical patent/ATE268604T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96906260T 1995-01-26 1996-01-26 Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren ATE268604T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (1)

Publication Number Publication Date
ATE268604T1 true ATE268604T1 (de) 2004-06-15

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906260T ATE268604T1 (de) 1995-01-26 1996-01-26 Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren

Country Status (25)

Country Link
EP (2) EP0809510B1 (de)
JP (2) JPH10513161A (de)
KR (2) KR100470739B1 (de)
CN (3) CN1589902A (de)
AT (1) ATE268604T1 (de)
AU (1) AU725351B2 (de)
BG (1) BG62599B1 (de)
BR (1) BR9606808A (de)
CA (1) CA2211443A1 (de)
CZ (1) CZ298711B6 (de)
DE (1) DE69632681T2 (de)
DK (1) DK0809510T3 (de)
EA (1) EA000096B1 (de)
EE (1) EE04453B1 (de)
ES (1) ES2220972T3 (de)
FI (1) FI119359B (de)
HK (1) HK1006356A1 (de)
HU (1) HUP9801746A3 (de)
NO (1) NO322744B1 (de)
NZ (1) NZ303405A (de)
PL (1) PL185364B1 (de)
PT (1) PT809510E (de)
RO (1) RO118634B1 (de)
SK (1) SK286497B6 (de)
WO (1) WO1996022788A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
AR035352A1 (es) * 2000-10-13 2004-05-12 Biogen Inc Anticuerpos anti-lt-beta-r humanizados
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
BR0317573A (pt) * 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
EP1583503A4 (de) * 2002-12-20 2006-08-09 Biogen Idec Inc Polyvalente lymphotoxin-beta-rezeptor-agonisten und therapeutische verwendung dafür
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1756162A1 (de) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Rezeptor-kupplungsmittel und ihre therapeutischen verwendungen
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
MX2009004134A (es) 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20110079705A (ko) * 2008-09-30 2011-07-07 제넨테크, 인크. 림포톡신 길항제에 대한 류마티스 관절염 반응을 예측하는 생물학적 마커
KR20140139480A (ko) * 2011-12-05 2014-12-05 이제니카 바이오테라퓨틱스, 인크. 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
SG10202001779UA (en) 2015-01-20 2020-04-29 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (de) 2020-12-02 2023-10-11 Vib Vzw Ltbr-agonist in kombinationstherapie gegen krebs
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
EP0536299B1 (de) * 1990-06-27 2001-06-06 Biogen, Inc. Oberflächenkomplexbildung von lymphotoxin
JPH08507201A (ja) * 1992-12-04 1996-08-06 バイオジェン，インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用

Also Published As

Publication number Publication date
EP0809510B1 (de) 2004-06-09
CZ236197A3 (cs) 1998-02-18
CA2211443A1 (en) 1996-08-01
EE04453B1 (et) 2005-04-15
MX9705629A (es) 1997-10-31
BG101855A (en) 1998-04-30
DE69632681D1 (de) 2004-07-15
KR100470739B1 (ko) 2005-09-02
CN1177302A (zh) 1998-03-25
WO1996022788A1 (en) 1996-08-01
PL321758A1 (en) 1997-12-22
HUP9801746A3 (en) 2000-11-28
FI973118A0 (fi) 1997-07-25
AU4970496A (en) 1996-08-14
KR100475492B1 (ko) 2005-03-14
JP2007169296A (ja) 2007-07-05
ES2220972T3 (es) 2004-12-16
SK286497B6 (sk) 2008-11-06
NZ303405A (en) 2000-02-28
CN1146442C (zh) 2004-04-21
FI119359B (fi) 2008-10-31
BG62599B1 (bg) 2000-03-31
CZ298711B6 (cs) 2008-01-02
NO973385D0 (no) 1997-07-22
EE9700255A (et) 1998-04-15
AU725351B2 (en) 2000-10-12
NO322744B1 (no) 2006-12-04
KR20040102364A (ko) 2004-12-04
CN1900116A (zh) 2007-01-24
RO118634B1 (ro) 2003-08-29
HUP9801746A2 (hu) 1998-11-30
CN1589902A (zh) 2005-03-09
FI973118A (fi) 1997-09-25
SK98697A3 (en) 2000-02-14
JPH10513161A (ja) 1998-12-15
EA199700144A1 (ru) 1997-12-30
PL185364B1 (pl) 2003-04-30
DE69632681T2 (de) 2005-06-09
BR9606808A (pt) 1997-12-30
DK0809510T3 (da) 2004-10-04
EA000096B1 (ru) 1998-08-27
KR19980701816A (ko) 1998-06-25
PT809510E (pt) 2004-09-30
EP0809510A1 (de) 1997-12-03
EP1407781A1 (de) 2004-04-14
HK1006356A1 (en) 1999-02-26
NO973385L (no) 1997-09-25

Similar Documents

Publication Publication Date Title
ATE268604T1 (de) Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
Martin et al. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Mohanam et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
Jimeno et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
Huraux et al. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries
EP0734264A4 (de) Verbindungen die spezifisch an kolorektale krebszellen binden und verfahren fuerihre herstellung
Aragane et al. Involvement of dectin-2 in ultraviolet radiation-induced tolerance
KR950002784A (ko) 종양 반응성 세포가 농후한 림프절의 결정방법, 이의 증식방법, 및 이를 입양 세포 요법에 사용하는 방법
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
BR0313033A (pt) anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
DK0771362T3 (da) Genetisk diagnose og farmaceutiske præparater til behandling af prostatacancer
DK0914345T3 (da) Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2)
YU83600A (sh) Adenozin a3 receptorski modulatori
Holyoake et al. Do we need more drugs for chronic myeloid leukemia?
AU3376297A (en) Human thyrotropin receptor compositions and use thereof
Li et al. Enhancing the efficacy of melanocortin 1 receptor-targeted radiotherapy by pharmacologically upregulating the receptor in metastatic melanoma
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
Cai et al. Adrenal proteins bound by a reactive intermediate of mitotane
Horton et al. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
US10947596B2 (en) Compositions and methods for identification, assessment, prevention, and treatment of cancer using NFS1 biomarkers and modulators
Bester et al. Cell-free protein synthesis in heart and skeletal muscles from polymyopathic hamsters
Sharp et al. Signaling through delta opioid receptors on murine splenic T cells and stably transfected Jurkat cells
Rosewicz et al. The amphicrine pancreatic cell line AR42J: a model system for combined studies on exocrine and endocrine secretion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0809510

Country of ref document: EP

REN Ceased due to non-payment of the annual fee